Phase I
As the dose of Sutro Biopharma’s ovarian cancer drug, STRO-002, increased in an ongoing Phase I dose-escalation trial, survival rates have also increased.
Like the Grinch’s heart at Christmas, the Nasdaq Exchange grew a little bigger this week with multiple life science companies raising hundreds of millions of dollars in initial public offerings.
It was a moderately busy week for clinical trial news, with some important reports coming out about COVID-19 vaccines. Here’s a look.
Researchers with the U.S. National Institutes of Allergy and Infectious Diseases (NIAID) published a letter in The New England Journal of Medicine describing the three-month immunogenicity levels in Moderna’s mRNA-1273 vaccine.
With 36 Janssen-sponsored studies and another nearly 50, it has supported, the Janssen Pharmaceutical Companies of Johnson & Johnson has a presence in more than 80 of the hematology studies presented at the 62nd American Society of Hematology (ASH) Annual Meeting & Exposition, December 5-8.
Despite a number of anti-psychotic medications available, there are no approved drugs to address underlying cognitive development issues. Cerevance aims to change that.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for December 1, 2020.
As the U.S. went into its Thanksgiving holiday week, clinical trial news was quieter than usual, although there was a lot of important news on the COVID-19 vaccine front. Here’s a look.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for November 24, 2020.
Although there was quite a bit of clinical trial news overall, the biggest focus was on COVID-19 vaccines, with the three leaders in the U.S. and Europe all presenting clinical trial news. Here’s a look.
PRESS RELEASES